Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resiquimod with gp100 and MAGE-3 Vaccines in Melanoma
NCT00960752Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2010
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of resiquimod in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Started May 2010; status: completed.
02
Drugs
resiquimod
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00960752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00960752.